PMID- 8630596
OWN - NLM
STAT- MEDLINE
DCOM- 19960701
LR  - 20151119
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 153
IP  - 5
DP  - 1996 May
TI  - Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled 
      budesonide. The impact of smoking.
PG  - 1519-29
AB  - The object of this investigation was to study the long-term effects of antiasthma 
      treatment on blood markers of inflammation and lung function in adult asthmatic 
      subjects. For this purpose 85 allergic and nonallergic asthmatic subjects were 
      randomized into three groups, which were given high-dose (1,600 micrograms/d) 
      inhaled budesonide, low-dose (400 micrograms/d) inhaled budesonide, and oral 
      theophylline (600 mg/d), respectively, and were followed for 11 mo with testing 
      of lung function and blood sampling for the assay in serum of eosinophil cationic 
      protein (ECP), eosinophil protein x/eosinophil derived neurotoxin (EPX/EDN) as 
      eosinophil markers, and myeloperoxidase (MPO) and lactoferrin (LF) as neutrophil 
      markers. Lung functions (FEV1% predicted, and histamine PC20) and the eosinophil 
      markers ECP and EPX/EDN were improved and reduced, respectively, by budesonide in 
      a dose-dependent and temporally parallel fashion. Theophylline did not alter lung 
      functions but reduced ECP and EPX/EDN after prolonged treatment. The treatment 
      efficacy of budesonide was attributed solely to an effect on nonsmoking asthmatic 
      subjects, since neither lung functions nor eosinophil markers changed in smokers 
      even with high-dose budesonide. MPO but not LF was reduced after several months 
      of treatment in all three groups, but only in nonsmokers. We conclude that ECP 
      and EPX/EDN may be used to monitor antiinflammatory treatment in asthmatic 
      patients, and that smoking asthmatic subjects are resistant to inhaled 
      corticosteroids.
FAU - Pedersen, B
AU  - Pedersen B
AD  - Department of Lung Medicine, University Hospital, Arhus, Denmark.
FAU - Dahl, R
AU  - Dahl R
FAU - Karlstrom, R
AU  - Karlstrom R
FAU - Peterson, C G
AU  - Peterson CG
FAU - Venge, P
AU  - Venge P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Aerosols)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Proteins)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Eosinophil Granule Proteins)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Neurotoxins)
RN  - 0 (Pregnenediones)
RN  - 51333-22-3 (Budesonide)
RN  - C137DTR5RG (Theophylline)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 3.1.- (Eosinophil-Derived Neurotoxin)
RN  - EC 3.1.- (Ribonucleases)
RN  - EC 3.1.27.5 (Ribonuclease, Pancreatic)
RN  - EC 3.4.21.- (Lactoferrin)
SB  - IM
MH  - Adult
MH  - Aerosols
MH  - Anti-Asthmatic Agents/administration & dosage/*therapeutic use
MH  - Anti-Inflammatory Agents/administration & dosage/*therapeutic use
MH  - Asthma/*drug therapy/physiopathology
MH  - Biomarkers/blood
MH  - Blood Proteins/analysis
MH  - Bronchodilator Agents/administration & dosage/*therapeutic use
MH  - Budesonide
MH  - Dose-Response Relationship, Drug
MH  - Eosinophil Granule Proteins
MH  - Eosinophil-Derived Neurotoxin
MH  - Eosinophils/*drug effects/physiology
MH  - Female
MH  - Follow-Up Studies
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Inflammation Mediators/blood
MH  - Lactoferrin/blood
MH  - Lung/drug effects/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Neurotoxins/analysis
MH  - Neutrophils/*drug effects/physiology
MH  - Peroxidase/blood
MH  - Pregnenediones/administration & dosage/*therapeutic use
MH  - Ribonuclease, Pancreatic/blood
MH  - *Ribonucleases
MH  - Smoking/*adverse effects/physiopathology
MH  - Theophylline/administration & dosage/therapeutic use
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.1164/ajrccm.153.5.8630596 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 1996 May;153(5):1519-29. doi: 
      10.1164/ajrccm.153.5.8630596.